Lion Biotechnologies Starts Dosing for Second Part of Trial

Lion Biotechnologies (NASDAQ:LBIO) announced the first patient dosing for the second cohort of an ongoing Phase 2 trial of LN-144 treating patients with metastatic melanoma.
As quoted in the press release:

This cohort utilizes the company’s generation 2 manufacturing process which includes cryopreservation of the outbound products.
“We are pleased to be able to offer a shorter manufacturing process for TIL to the melanoma patients enrolling in Cohort 2 of LN-144 trial. This process reduces the time from excision to infusion from approximately six weeks to just over three weeks and includes cryopreservation for the outbound product,” said Maria Fardis, PhD, MBA, Lion Biotechnologies President and Chief Executive Officer. “Reducing the time from excision to infusion is critical for treatment of advanced melanoma patients. This process provides greater flexibility for physicians and patients in scheduling the time of the infusion due to the cryopreserved nature of the TIL product. Further, the shorter process increases the manufacturing flexibility for Lion leading to lower production costs.”

Click here to read the full press release.

Source: www.marketwired.com